Omeros defends its drug, but still won’t answer basic questions
Omeros sought to defend its experimental drug OMS721 with a press release responding to my questions about the drug. But it didn't clear much up.
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
